Published in Cancer Res on April 10, 2012
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer (2013) 2.60
A NIK-IKKα module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1. Cancer Cell (2013) 1.21
HER2 and breast cancer stem cells: more than meets the eye. Cancer Res (2013) 1.14
Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity. Autophagy (2014) 1.14
RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One (2013) 1.08
Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases. Clin Exp Metastasis (2013) 0.97
Targeting RANKL in metastasis. Bonekey Rep (2014) 0.95
Emerging roles of the tumor-associated stroma in promoting tumor metastasis. Cell Adh Migr (2012) 0.94
T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer. PLoS One (2013) 0.94
Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol (2014) 0.92
RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis (2013) 0.91
Genetics of breast cancer bone metastasis: a sequential multistep pattern. Clin Exp Metastasis (2014) 0.87
The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis. Oncotarget (2015) 0.87
Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration. Breast Cancer Res (2012) 0.83
Concise review: breast cancer stem cells: regulatory networks, stem cell niches, and disease relevance. Stem Cells Transl Med (2014) 0.83
The NF-κB Pathway and Cancer Stem Cells. Cells (2016) 0.82
Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. J Invest Dermatol (2015) 0.81
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res (2015) 0.81
Reproduction and breast cancer risk. Breast Care (Basel) (2014) 0.80
Steroid Hormones, Steroid Receptors, and Breast Cancer Stem Cells. J Mammary Gland Biol Neoplasia (2015) 0.80
RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. Br J Cancer (2015) 0.79
The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases. Oncotarget (2016) 0.79
Role of RANKL/RANK in primary and secondary breast cancer. World J Orthop (2013) 0.79
Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers. Oncotarget (2016) 0.79
RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB-mediated epithelial-mesenchymal transition. PLoS One (2014) 0.78
Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells. Oncotarget (2016) 0.77
CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells. Oncotarget (2016) 0.77
Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome. Oncotarget (2016) 0.77
Breast cancer likely to metastasise to bone if RANK expression high. Bonekey Rep (2012) 0.75
Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines. Int J Clin Exp Pathol (2015) 0.75
RANKL enhances the effect of an antagonist of inhibitor of apoptosis proteins (cIAPs) in RANK-positive breast cancer cells. J Bone Oncol (2013) 0.75
Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment? J Clin Med (2013) 0.75
HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res (2016) 0.75
RANK-RANKL signalling in cancer. Biosci Rep (2016) 0.75
Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors. PLoS One (2015) 0.75
RANKL inhibitors for osteosarcoma treatment: hope and caution. Ann Transl Med (2016) 0.75
The seventh ENBDC workshop on methods in mammary gland development and cancer. Breast Cancer Res (2015) 0.75
The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy. Onco Targets Ther (2017) 0.75
Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort. Cancer Prev Res (Phila) (2017) 0.75
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell (2011) 4.79
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66
Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. Genes Dev (2009) 2.91
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol (2008) 2.43
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Telomere lengthening early in development. Nat Cell Biol (2007) 2.02
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood (2011) 1.98
Gall bladder and extrahepatic bile duct lymphomas: clinicopathological observations and biological implications. Am J Surg Pathol (2010) 1.59
A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem (2002) 1.54
Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther (2010) 1.53
A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol (2008) 1.51
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis (2007) 1.42
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate (2008) 1.42
Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. Genes Dev (2007) 1.33
Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res (2007) 1.31
Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem (2004) 1.30
The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation. Genes Dev (2013) 1.29
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther (2007) 1.28
Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. Breast (2012) 1.27
In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica (2011) 1.22
Orbital lymphoma: imaging features and differential diagnosis. Insights Imaging (2012) 1.21
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica (2013) 1.19
Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res (2006) 1.18
Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone (2008) 1.18
In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res (2002) 1.17
Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity. Clin Cancer Res (2009) 1.14
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget (2012) 1.14
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther (2008) 1.13
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res (2002) 1.12
Filamin B plays a key role in vascular endothelial growth factor-induced endothelial cell motility through its interaction with Rac-1 and Vav-2. J Biol Chem (2010) 1.11
Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res (2003) 1.10
RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev (2007) 1.08
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clin Cancer Res (2014) 1.06
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res (2005) 1.04
Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res (2012) 1.04
Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis. Am J Surg Pathol (2011) 1.04
Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Hum Pathol (2013) 1.03
Role of human Ku86 in telomere length maintenance and telomere capping. Cancer Res (2004) 1.03
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int J Cancer (2013) 1.02
Telomere shortening relaxes X chromosome inactivation and forces global transcriptome alterations. Proc Natl Acad Sci U S A (2009) 1.02
Role of TRF2 in the assembly of telomeric chromatin. Cell Cycle (2008) 1.01
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther (2008) 1.00
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. Breast Cancer Res (2011) 1.00
Role of mammalian Rad54 in telomere length maintenance. Mol Cell Biol (2003) 0.99
Chromatin dynamics coupled to DNA repair. Epigenetics (2009) 0.99
CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med (2013) 0.99
High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica (2011) 0.98
Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence. Ann Surg Oncol (2010) 0.97
Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J Exp Med (2013) 0.97
Biological convergence of cancer signatures. PLoS One (2009) 0.97
Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res (2009) 0.96
Regulation of ubiquitous 6-phosphofructo-2-kinase by the ubiquitin-proteasome proteolytic pathway during myogenic C2C12 cell differentiation. FEBS Lett (2003) 0.96
Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human breast cancer cells. Mol Cancer Ther (2007) 0.95
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 0.95
Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol (2013) 0.95
A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol (2003) 0.94
RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat (2014) 0.93
Interaction between HERC1 and M2-type pyruvate kinase. FEBS Lett (2003) 0.93
Novel UBE3A mutations causing Angelman syndrome: different parental origin for single nucleotide changes and multiple nucleotide deletions or insertions. Am J Med Genet A (2009) 0.93
PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis (2008) 0.92
Identification of NOG as a specific breast cancer bone metastasis-supporting gene. J Biol Chem (2012) 0.92
Integrative analysis of a cancer somatic mutome. Mol Cancer (2007) 0.92
BMP-2 regulation of PTHrP and osteoclastogenic factors during osteoblast differentiation of C2C12 cells. J Cell Physiol (2008) 0.92
RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis (2013) 0.91
[Diverticular disease of the cecal appendix]. Cir Esp (2005) 0.91
RANKL inhibition: from mice to men (and women). Adv Exp Med Biol (2007) 0.90
Deficient mismatch repair improves organismal fitness and survival of mice with dysfunctional telomeres. Genes Dev (2007) 0.89
cAMP inhibits TGFbeta1-induced in vitro angiogenesis. FEBS Lett (2004) 0.89
Down-regulation of spinophilin in lung tumours contributes to tumourigenesis. J Pathol (2011) 0.89
Molecular mechanisms involved in the adenosine A and A receptor-induced neuronal differentiation in neuroblastoma cells and striatal primary cultures. J Neurochem (2005) 0.88
Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol (2007) 0.87
Molecular mechanisms behind the resistance of cisplatin in germ cell tumours. Clin Transl Oncol (2009) 0.87
Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One (2010) 0.87
The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway. Biochem Pharmacol (2007) 0.87
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res (2013) 0.87
Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo. Cancer Epidemiol Biomarkers Prev (2008) 0.87
Characterization of the p53 response to oncogene-induced senescence. PLoS One (2008) 0.86
Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells (2013) 0.85
WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. Br J Haematol (2014) 0.85
Genetic interactions: the missing links for a better understanding of cancer susceptibility, progression and treatment. Mol Cancer (2008) 0.84
Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone (2010) 0.84
Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors. Genes Chromosomes Cancer (2012) 0.83
RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat (2012) 0.83
Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. Clin Exp Metastasis (2006) 0.83
The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Ann N Y Acad Sci (2012) 0.82
Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach. J Invest Dermatol (2010) 0.82
RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase. Breast Cancer Res Treat (2014) 0.82
Development and characterization of an isogenic cell line with a radioresistant phenotype. Clin Transl Oncol (2012) 0.82
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res (2015) 0.81
RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. J Thorac Oncol (2014) 0.81